EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Targeting JAK–STAT signaling for autoimmune diseases: current understanding, clinical advances, and emerging directions

Zhimin Wu, Gaojian Lian, Lvheng He, Pingping Hu, Yujia Guo, Zehong Su

Immunology & Cell Biology · 2026

DOI: 10.1111/imcb.70078 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Immunology & Cell Biology, 2026. Verfasst von Zhimin Wu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, Basic Medical College, University of South China, Hengyang, Hunan, China. Hauptthemen laut MEDLINE: Autoimmune Diseases, STAT Transcription Factors, Signal Transduction, Janus Kinases. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 218 Literaturangaben. Gefördert von: Natural Science Foundation of Hunan Province, Key Grant of Research and Development in Hunan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Janus kinase (JAK)‐signal transducer and activator of transcription (STAT) pathway is a key regulatory signaling cascade for the survival, activation, maturation, and differentiation of immune cells through interactions with cytokine receptors and transcription factors. Growing evidence indicates that autoimmune disorders are markedly affected by the JAK–STAT axis. Understanding the architecture and functions of the JAK–STAT axis has spurred the creation and authorization of a number of medications for managing autoimmune conditions in clinical settings. A mass of therapeutic agents (e.g., JAKinibs tofacitinib, baricitinib, STATinibs Stattic, FLLL32) and non‐coding RNA have been used in research in preclinical experiments or/and clinical trials and demonstrate significant potential for treating autoimmune diseases. Nevertheless, concerns about these medicines' long‐term safety and possible adverse consequences still exist. This narrative overview elaborates on the exact molecular underpinnings of the JAK–STAT axis, while also exploring the links among this pathway, adaptive immune cells, and autoimmune disorders. We also summarize the recently developed inhibitors of this pathway along with the present issues and future directions in the field.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Autoimmune DiseasesSTAT Transcription FactorsSignal TransductionJanus KinasesHumansAnimalsMolecular Targeted Therapy

Stichwörter der Autor:innen

Autoimmune diseasesJAK–STAT signaling pathwayimmune cellsinhibitors

Substanzen

STAT Transcription FactorsJanus Kinases

Autor:innen und Institutionen

  • Department of Biochemistry and Molecular Biology, Basic Medical College, University of South China, Hengyang, Hunan, China.
  • Institute of Cytobiology and Genetic, Basic Medical College, University of South China, Hengyang, Hunan, China.

Förderung

  • Natural Science Foundation of Hunan Province
  • Key Grant of Research and Development in Hunan Province

Zitieren

APA

Wu, Z., Lian, G., He, L., Hu, P., Guo, Y., & Su, Z. (2026). Targeting JAK–STAT signaling for autoimmune diseases: current understanding, clinical advances, and emerging directions. Immunology & Cell Biology. https://doi.org/10.1111/imcb.70078

Vancouver

Wu Z, Lian G, He L, Hu P, Guo Y, Su Z. Targeting JAK–STAT signaling for autoimmune diseases: current understanding, clinical advances, and emerging directions. Immunology & Cell Biology. 2026. doi:10.1111/imcb.70078

BibTeX
@article{Wu2026,
  author = {Wu, Zhimin and Lian, Gaojian and He, Lvheng and Hu, Pingping and Guo, Yujia and Su, Zehong},
  title = {Targeting JAK–STAT signaling for autoimmune diseases: current understanding, clinical advances, and emerging directions},
  journal = {Immunology & Cell Biology},
  year = {2026},
  doi = {10.1111/imcb.70078}
}
Kostenlos starten →